Page last updated: 2024-08-24

ibandronic acid and Secondary Hyperparathyroidism

ibandronic acid has been researched along with Secondary Hyperparathyroidism in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (66.67)	29.6817
2010's	1 (33.33)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Arias, M; Barros, X; Blasco, M; Campistol, JM; Cases, A; Durán, CE; Torregrosa, JV	1
Bals, G; Bergner, R; Henrich, D; Hoffmann, M; Lenz, T; Ullmann, M; Uppenkamp, M	1
Bauss, F; Geng, Z; Malluche, HH; Monier-Faugere, MC	1

Trials

2 trial(s) available for ibandronic acid and Secondary Hyperparathyroidism

Article	Year
Successful treatment of calcific uraemic arteriolopathy with bisphosphonates. Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia, 2012, May-14, Volume: 32, Issue:3 Topics: Aged; Alendronate; Alkaline Phosphatase; Arterioles; Calciphylaxis; Calcium; Comorbidity; Diphosphonates; Disease Progression; Etidronic Acid; Female; Humans; Hyperparathyroidism, Secondary; Ibandronic Acid; Kidney Transplantation; Male; Middle Aged; Parathyroid Hormone; Parathyroidectomy; Phosphates; Prospective Studies; Renal Dialysis; Risedronic Acid; Skin; Uremia	2012
High bone-binding capacity of ibandronate in hemodialysis patients. International journal of clinical pharmacology research, 2005, Volume: 25, Issue:3 Topics: Adult; Aged; Bone and Bones; Bone Density; Bone Density Conservation Agents; Bone Resorption; Diphosphonates; Humans; Hyperparathyroidism, Secondary; Ibandronic Acid; Kidney Failure, Chronic; Middle Aged; Renal Dialysis; Treatment Outcome	2005

Article

Year

Successful treatment of calcific uraemic arteriolopathy with bisphosphonates.

Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia, 2012, May-14, Volume: 32, Issue:3

Topics: Aged; Alendronate; Alkaline Phosphatase; Arterioles; Calciphylaxis; Calcium; Comorbidity; Diphosphonates; Disease Progression; Etidronic Acid; Female; Humans; Hyperparathyroidism, Secondary; Ibandronic Acid; Kidney Transplantation; Male; Middle Aged; Parathyroid Hormone; Parathyroidectomy; Phosphates; Prospective Studies; Renal Dialysis; Risedronic Acid; Skin; Uremia

2012

High bone-binding capacity of ibandronate in hemodialysis patients.

International journal of clinical pharmacology research, 2005, Volume: 25, Issue:3

Topics: Adult; Aged; Bone and Bones; Bone Density; Bone Density Conservation Agents; Bone Resorption; Diphosphonates; Humans; Hyperparathyroidism, Secondary; Ibandronic Acid; Kidney Failure, Chronic; Middle Aged; Renal Dialysis; Treatment Outcome

2005

Other Studies

1 other study(ies) available for ibandronic acid and Secondary Hyperparathyroidism

Article	Year
Short-term administration of the bisphosphonate ibandronate increases bone volume and prevents hyperparathyroid bone changes in mild experimental renal failure. Clinical nephrology, 2000, Volume: 54, Issue:1 Topics: Alkaline Phosphatase; Animals; Bone and Bones; Bone Resorption; Calcium; Chronic Kidney Disease-Mineral and Bone Disorder; Creatinine; Diphosphonates; Female; Hyperparathyroidism, Secondary; Ibandronic Acid; Kidney Failure, Chronic; Osteocalcin; Parathyroid Hormone; Phosphorus; Rats; Rats, Sprague-Dawley	2000

Article

Year

Short-term administration of the bisphosphonate ibandronate increases bone volume and prevents hyperparathyroid bone changes in mild experimental renal failure.

Clinical nephrology, 2000, Volume: 54, Issue:1

Topics: Alkaline Phosphatase; Animals; Bone and Bones; Bone Resorption; Calcium; Chronic Kidney Disease-Mineral and Bone Disorder; Creatinine; Diphosphonates; Female; Hyperparathyroidism, Secondary; Ibandronic Acid; Kidney Failure, Chronic; Osteocalcin; Parathyroid Hormone; Phosphorus; Rats; Rats, Sprague-Dawley

2000